This three party relationship has been established to support a previously established collaboration between Icagen and Pfizer for the discovery of compounds which modulate specific sodium ion channels as potential new treatments for pain and related disorders.
Kay Wagoner, president and CEO of Icagen, said: “We expect that this collaboration will provide important information that may further accelerate our efforts, together with Pfizer, to advance novel sodium channel modulators into clinical development for the treatment of pain and related disorders.”